Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential

BenzingaDec 17 08:23 ET

Immutep's Phase 1 Trial Shows Favorable Safety Profile of Drug Candidate for Autoimmune Disease; Shares Down 3%

MT NewswiresDec 16 20:35 ET

Immutep And Monash University Announce First Publication In "Science Immunology" Detailing How Human LAG-3 Binds to MHC Class II

BenzingaDec 16 08:16 ET

Maxim Group Maintains Immutep(IMMP.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsDec 13 14:31 ET · Ratings

Immutep Announces Results From Cohort B of TACTI-003 Trial

TipRanksDec 12 08:20 ET

Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%

MT NewswiresDec 11 22:38 ET